Larazotide

InChIKey
ORFLZNAGUTZRLQ-ZMBVWFSWSA-N

SMILES
CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CN

• In adults with celiac disease, larazotide and placebo had comparable safety. (Gastroenterology, 2015)
• In patients with coeliac disease during gluten challenge, larazotide and placebo had similar adverse event rates. (Alimentary pharmacology & therapeutics, 2013)
• In patients with celiac disease, larazotide was generally well tolerated. (The American journal of gastroenterology, 2012)
• In children with MISC, no adverse events related to larazotide were reported. (Science translational medicine, 2025)
• Four children with MIS-C given larazotide on top of their usual treatment had no reported adverse effects. (Critical care explorations, 2022)
• In the celiac disease trial, no serious adverse events were observed. (The American journal of gastroenterology, 2012)
• In the celiac disease trial, headache and urinary tract infection were the most common adverse events, but the abstract did not give rates by treatment. (The American journal of gastroenterology, 2012)
• In mice, AT1001 completely reversed DSS-associated mortality compared with DSS without AT1001. (Annals of the New York Academy of Sciences, 2017)

The doses that these studies used. They are not recommendations.